Skip to content

Study · Randomized controlled trial · n = 159 · 2016

5 results

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.

Bhandari M, Jin L, See K, Burge R, Gilchrist N, Witvrouw R, Krohn KD, Warner MR, Ahmad QI, Mitlak B

Clinical orthopaedics and related research1 Mar 2016Cited by 68 (Europe PMC)

PMID26932738 (opens in a new tab)PMCIDPMC4814417 (opens in a new tab)DOI10.1007/s11999-015-4669-z (opens in a new tab)PepBankPUB-26932738
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with femoral neck fractures, freedom from revision surgery was 84% with teriparatide versus 88% with placebo, without significant difference.

    In plain wordsIn patients with hip fractures, freedom from revision surgery did not differ significantly between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeNo revision surgery at 12 months
    Study

    n = 157

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Patients without revision surgery
    84%
    teriparatide, 12 months
    Patients without revision surgery
    88%
    placebo, 12 months

    Source sentences

    Summary
    After exclusions, the proportion of patients who did not undergo revision surgery at 12 months (primary endpoint) was not different between the study and placebo groups, at 88% in the placebo group (90% CI, 0.79-0.93) versus 84% in the teriparatide group (90% CI, 0.75-0.90; p = 0.743).
    2 context sentences
    Summary · context
    The two prospective, randomized double-blind, placebo-controlled Phase III studies were designed to evaluate the effect of subcutaneous teriparatide (20 μg/day) for 6 months versus placebo on fracture healing at 24 months.
    Summary · context
    A total of 159 patients were randomized in the two trials (81 placebo, 78 teriparatide).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with femoral neck fractures, revision surgery occurred in 17% with teriparatide versus 14% with placebo at 12 months.

    In plain wordsIn patients with hip fractures, revision surgery occurred in 17% with teriparatide versus 14% with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedRevision surgery at 12 months before exclusions
    Study

    n = 159

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Revision surgery
    17%
    teriparatide
    Revision surgery
    14%
    placebo

    Source sentences

    Summary
    The proportion of patients undergoing revision surgery at 12 months was 14% (11 of 81) in the placebo group versus 17% (13 of 78) in the teriparatide group.
    2 context sentences
    Summary · context
    The two prospective, randomized double-blind, placebo-controlled Phase III studies were designed to evaluate the effect of subcutaneous teriparatide (20 μg/day) for 6 months versus placebo on fracture healing at 24 months.
    Summary · context
    A total of 159 patients were randomized in the two trials (81 placebo, 78 teriparatide).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with femoral neck fractures, radiographic healing was 73% with teriparatide versus 75% with placebo, without significant difference.

    In plain wordsIn patients with hip fractures, radiographic healing did not differ significantly between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRadiographic fracture healing at 12 months
    Study

    n = 159

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Radiographic fracture healing
    73%
    teriparatide, 12 months
    Radiographic fracture healing
    75%
    placebo, 12 months
    Odds ratio, radiographic healing
    0.89 odds ratio
    teriparatide versus placebo

    Source sentences

    Summary
    There also were no differences between groups in the proportion of patients achieving radiographic fracture healing at 12 months (75% [61 of 81] placebo versus 73% [57 of 78] teriparatide; odds ratio, 0.89; 90% CI, 0.46-1.72; p = 0.692)
    2 context sentences
    Summary · context
    The two prospective, randomized double-blind, placebo-controlled Phase III studies were designed to evaluate the effect of subcutaneous teriparatide (20 μg/day) for 6 months versus placebo on fracture healing at 24 months.
    Summary · context
    A total of 159 patients were randomized in the two trials (81 placebo, 78 teriparatide).
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with femoral neck fractures, adverse events occurred in 45% with teriparatide versus 49% with placebo, without significant difference.

    In plain wordsIn patients with hip fractures, adverse event frequency did not differ significantly between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAdverse events
    Study

    n = 159

    Comparator
    placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Patients reporting adverse events
    45%
    teriparatide, 6-month treatment period
    Patients reporting adverse events
    49%
    placebo, 6-month treatment period

    Source sentences

    Summary
    The frequency of patients reporting adverse events was 49% [40 of 81] in the placebo group versus 45% [35 of 78] in the teriparatide group (p = 0.634) during the 6-month treatment period.
    2 context sentences
    Summary · context
    The two prospective, randomized double-blind, placebo-controlled Phase III studies were designed to evaluate the effect of subcutaneous teriparatide (20 μg/day) for 6 months versus placebo on fracture healing at 24 months.
    Summary · context
    A total of 159 patients were randomized in the two trials (81 placebo, 78 teriparatide).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with femoral neck fractures, pain control during ambulation did not differ between teriparatide and placebo.

    In plain wordsIn patients with hip fractures, pain control during walking did not differ between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePain control during ambulation
    Study

    n = 119

    Comparator
    placebo
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 μg/day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Pain during ambulation measure
    91%
    teriparatide
    Pain during ambulation measure
    92%
    placebo
    Odds ratio, pain during ambulation
    0.91 odds ratio
    teriparatide versus placebo

    Source sentences

    Summary
    or in measures of pain control (such as pain during ambulation, 92% [55 of 62] placebo versus 91% [52 of 57] teriparatide; odds ratio, 0.91; 90% CI, 0.25-3.37; p = 0.681).
    2 context sentences
    Summary · context
    The two prospective, randomized double-blind, placebo-controlled Phase III studies were designed to evaluate the effect of subcutaneous teriparatide (20 μg/day) for 6 months versus placebo on fracture healing at 24 months.
    Summary · context
    A total of 159 patients were randomized in the two trials (81 placebo, 78 teriparatide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.